

## UK clinical trial database

Verified* cell therapy clinical tria	als in the UK	* by Cell	Therapy Catap	oult							
Project summary	Lead institution/ company	Present stage of development		Recruitment target for current trial	Current trial still actively recruiting	Cell type	Autologous/ Allogeneic	Cell source	Disease area	Indication	Contact
Randomised control trial to compare the effects of G-CSF and autologous bone marrow progenitor cells infusion in patients with ischaemic heart disease	Barts Health NHS Trust, Queen Mary University of London	Phase 2	2005	90	Recruitment completed, in follow up	Bone marrow mononuclear cells	Autologous	Bone marrow derived	Cardiovascular	Heart failure secondary to ischaemic heart disease	Professor Anthony Mathur, William Harvey Research Institute, Queen Mary University (a.mathur@qmul.ac.uk)
Autologous bone marrow derived mononuclear cells for acute myocardial infarction. Combines stem cell delivery with primary angioplasty within 5 hours post event	Barts Health NHS Trust, Queen Mary University of London, University College London	Phase 1/2	2007	70	Yes	Bone marrow mononuclear cells	Autologous	Bone marrow derived	Cardiovascular	Acute myocardial infarction	Professor Anthony Mathur, William Harvey Research Institute, Queen Mary University (a.mathur@qmul.ac.uk)
Autologous bone marrow derived mononuclear cells for dilated cardiomyopathy, delivered via intracoronary injection	Barts Health NHS Trust, Queen Mary University of London	Phase 1/2	2010	60	Yes	Bone marrow mononuclear cells	Autologous	Bone marrow derived	Cardiovascular	Dilated cardiomyopathy	Professor Anthony Mathur, William Harvey Research Institute, Queen Mary University (a.mathur@qmul.ac.uk)
Expanded adult haematopoietic stem cells for autologous infusion to patients with myocardial ischaemia	Imperial College London	Phase 1/2	2011	42	Yes	Expanded haematopoietic CD34+ stem cells	Autologous	Bone marrow	Cardiovascular	Localised myocardial dysfunction	Anne Bradshaw, Imperial College Healthcare NHS Trust (anne.bradshaw@imperial.nhs.uk 0203 313 2056)
Stem cells in rapidly evolving active multiple sclerosis (STREAMS)	Imperial College London	Phase 2	2012	13	Yes	Mesenchymal stromal cells	Autologous	Bone marrow	Neurological	Relapsing remitting multiple sclerosis/ secondary progressive multiple sclerosis/ primary progressive multiple sclerosis	Anne Bradshaw, Imperial College Healthcare NHS Trust (anne.bradshaw@imperial.nhs.uk 0203 313 2056)
Fetal brain tissue transplant for Parkinson's disease (TRANSEURO: An Innovative Approach for the Treatment of Parkinson's Disease)	Cambridge University	Phase 1/2	2012	20 transplanted patients, 20 controls	Yes, but all patients recruited to this study have been previously enrolled in the Transeuro observational study and all patients are selected from the observational study to take part in the transplant study	Fetal brain	Allogeneic		Neurological	Parkinson's disease	Danielle Daft, University of Cambridge
Autologous bone marrow derived CD34+ cells for ischemic stroke, administered within 7 days post event	Imperial College London	Phase 1	2007	10	Yes	Expanded CD34+ cells	Autologous	Bone marrow derived	Neurological	Ischemic stroke	Professor Nagy Habib, Imperial College London (nagy.habib@imperial.ac.uk)



## UK clinical trial database

Verified* cell therapy clinical tria	als in the UK	* by Cell	Therapy Catap	oult							
Project summary	Lead institution/ company	Present stage of development		Recruitment target for current trial	Current trial still actively recruiting	Cell type	Autologous/ Allogeneic	Cell source	Disease area	Indication	Contact
ReN001: CTX neural progenitor cells for stroke disability	ReNeuron	Phase 1	2010	12	Yes	Neural	Allogeneic	Brain (cortex)	Neurological	Stroke disability	Dr John Sinden, ReNeuron Group plc (info@reneuron.com)
Cytovir CMV (cytomegalovirus) adoptive T cell therapy for CMV immunity post bone marrow transplantation from sibling donor (IMPACT study). T cells derived from sibling donor providing bone marrow	Cell Medica	Phase 3	2008	Minimum 70	Yes	T cell	Allogeneic	Peripheral blood stem cells	Oncology/ Blood	CMV reactivation following allogeneic haematopoietic stem cell transplantation (prophylactic)	Karen Hodgkin, Cell Medica (karen.hodgkin@cellmedica.co.uk)
Cytomegalovirus (CMV) vaccination using adoptive T cell transfer following haematopoietic stem cell transplantation (ACE/ASPECT study)	Cell Medica with Birmingham University	Phase 2	2010	42	Yes	T cell	Allogeneic	Peripheral blood stem cells	Oncology/ Blood	CMV reactivation following allogeneic haematopoietic stem cell transplantation (pre-emptive)	Karen Hodgkin, Cell Medica (karen.hodgkin@cellmedica.co.uk)
Adoptive T cell therapy for the reconstitution of immunity to adenovirus (ADV) in paediatric patients following bone marrow transplantation	Cell Medica	Phase 1/2	2012	15 treated patients	Yes	T cell	Allogeneic	Immune cells	Oncology/ Blood	ADV in paediatric patients following bone marrow transplantation	Karen Hodgkin, Cell Medica (karen.hodgkin@cellmedica.co.uk)
Patients with high-risk B cell precursor acute lymphoblastic leukaemia are treated with donorderived EBV-specific cytotoxic T-lymphocytes transduced with the SFGaCD19-CD3ζ retroviral vector following allogeneic haematopoietic stem cell transplantation	University College London	Phase 1/2	2012	75	Yes	CD8 cytotoxic T cell	Allogeneic	Peripheral blood mononuclear cells	Oncology	Acute lymphoblastic leukaemia	Dr Zahid Sattar, University College London, (z.sattar@ucl.ac.uk)
T cell suicide gene therapy following haploidentical stem cell transplantation. Infusion of transduced donor T cells expressing HSVTK in the haploidentical setting, to enable removal of donor T cells in the event of GvHD.	Great Ormond Street Hospital, London	Phase 1/2	2011	10	Yes	Donor T cells	Allogeneic	Peripheral blood	Blood	Patients with primary immunodeficiencies, haematological malignancies or metabolic disorders undergoing haploidentical transplant	Anne-Marie McNicol, Clinical Trials Coordinator, UCL Institute of Child Health, London (anne-marie.mcnicol@ucl.ac.uk)
Autologous CD34+ haematopoietic cells for Crohn's disease	European Group for Blood and Marrow Transplantation (EMBT)	Phase 2/3	2006	45	No	CD34+ stem cells	Autologous	Bone marrow derived	Gastroenterology	Crohn's disease	Prof Hawkey, NDDC, West Block, E Floor, University Hospital, QMC, Nottingham NG7 2UH (cj.hawkey@nottingham.ac.uk) Trial Coordinator: Miranda Clark (astic@nottingham.ac.uk)
Repeated infusions of autologous CD133+ bone marrow stem cells for liver cirrhosis	Birmingham University, Edinburgh University	Phase 2	2009	81	Yes	CD133+ haematopoietic stem cells	Autologous	Bone marrow derived	Gastroenterology (Liver)	Liver cirrhosis	Dr Philip Newsome, University of Birmingham (p.n.newsome@bham.ac.uk)
Autologous expanded haemopoietic cells for liver insufficiency. Adminstered after 7 days expansion via the portal vein or hepatic artery	Imperial College London	Phase 1/2	2005		Yes	Expanded CD34+	Autologous	Derived by leukapheresis	Gastroenterology (Liver)	Liver insufficiency	Professor Nagy Habib, Imperial College London (nagy.habib@imperial.ac.uk)



HIK	clinical	trial	database
UK	cimicai	uriai	ualabase

on cliffical trial database											
/erified* cell therapy clinical trials in the UK * by Cell Therapy Catapult											
Project summary	Lead institution/ company	Present stage of development	Year current trial started	Recruitment target for current trial	Current trial still actively recruiting	Cell type	Autologous/ Allogeneic	Cell source	Disease area	Indication	Contact
Autologous cultured human limbal epithelium for limbal stem cell deficiency (ophthalmology)	Newcastle University	Phase 2	2012	24	Yes	Corneal	Autologous	Limbus	Ophthalmology	Limbal stem cell deficiency	Professor Francisco C Figueiredo, Newcastle University, UK
Corneal stem cells (allogeneic limbal epithelial stem cells on amniotic membrane)	Edinburgh University, Scottish National Blood Transfusion Service	Phase 1/2	2011	20	Yes	Corneal	Allogeneic	Limbus	Ophthalmology	Corneal stem cell deficiency	Margaret MacDonald, Research Nurse co- ordinator PAEP
Retinal pigment epithelial cell replacement for Stargardt's disease	Advanced Cell Technology	Phase 1/2	2011	12	Yes	Retinal pigment epithelium cell replacement derived from human embryonic stem cell	Allogeneic	Embryonic	Ophthalmology	Stargardt's disease	Dr. James Bainbridge, Moorefields Eye Hospital, London (j.bainbridge@ucl.ac.uk)
Autologous expanded CD34+ subset for diabetes. Administered after 21 days expansion	Imperial College London	Phase 1	2007		Yes	Expanded CD34+ subset	Autologous	Derived by leukapheresis	Diabetes	Diabetes type I or II	Professor Nagy Habib, Imperial College London (nagy.habib@imperial.ac.uk)
Autologous mesenchymal stem cells (MSCs) for knee meniscal repair. MSCs grown on biological scaffold for 2 weeks then surgically implanted	Azellon Cell Therapeutics	Phase 1/2	2012	10	Yes	Mesenchymal stem cells	Autologous	Bone marrow	Bone and cartilage	Knee meniscus repair	Professor Anthony Hollander, (CSO at Azellon); Univeristy of Bristol (anthony.hollander@bristol.ac.uk)

Unverified cell therapy clinical tr	ials in the UK										
Project summary	Lead institution/ company	Present stage of development	Year current trial started	Recruitment target for current trial	Current trial still actively recruiting	Cell type	Autologous/ Allogeneic	Cell source	Disease area	Indication	Public source of information
CMV TCR gene therapy: A phase I safety, toxicity and feasibility study of adoptive immunotherapy with CMV TCR-transduced donor-derived T cells for recipients of allogeneic haematopoietic stem cell transplantation				10		CMV TCR-transduced donor T cells	Allogeneic		Oncology	CMV reactivation/infection in post allogeneic haematopoietic stem cell transplant recipients	EU Clinical Trials Register. EudraCT number: 2008-006649-18 (www.clinicaltrialsregister.eu/ctr- search/trial/2008-006649-18/GB)
Autologous chondrocyte transplantation/implantation versus existing treatments (ACTIVE study) for patients who have had a failed primary treatment for chondral defect(s) in the knee				400		Chondrocyte	Autologous		Bone and cartilage	Chondral defects in the knee	International Standard Randomised Controlled Trial Number Register. ISRCTN48911177 (www.controlled- trials.com/ISRCTN48911177/Autologous+Ch ondrocyte)
Using autologous mesenchymal stem cells to treat human fractures (PACINO study)				60		Mesenchymal stem cells	Autologous		Bone and cartilage	Bone healing	International Standard Randomised Controlled Trial Number Register. ISRCTN09755245 (www.controlled- trials.com/ISRCTN09755245)